RecruitingPhase 2NCT04745949

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

Studying Primary mediastinal large B-cell lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Ranjit Nair
M.D. Anderson Cancer Center
Intervention
Brentuximab Vedotin(drug)
Enrollment
31 target
Eligibility
18 years · All sexes
Timeline
20212027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04745949 on ClinicalTrials.gov

Other trials for Primary mediastinal large B-cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Primary mediastinal large B-cell lymphoma

← Back to all trials